ReviewCellular and molecular life sciences : CMLS2021
Twenty years of research on HPV vaccines based on genetically modified lactic acid bacteria: an overview on the gut-vagina axis.
Review in Cellular and molecular life sciences : CMLS, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 48 citations in OpenAlex.
- Genetically Modified Lactic Acid Bacteria in the EU Food Chain: Applications, Benefits, and Risk Assessment.International journal of molecular sciences · 2026Review
- Genetically Modified Lactic Acid Bacteria: a Promising Mucosal Delivery Vector for Vaccines.Probiotics and antimicrobial proteins · 2026Review
- Review
- Inhibitory effect ofFrontiers in cellular and infection microbiology · 2026Article
- Human Papillomavirus: An Old New History.Pathogens (Basel, Switzerland) · 2025Review
- Trends and hotspots in research of virus and gastrointestinal mucosal immunity: a bibliometric analysis of four decades.Virology journal · 2025Article
- Harnessing the Power of Microbiota: How Do KeyBiology · 2025Review
- The Role of the Vaginal Microbiome in Immune Modulation in Cervical Cancer: Composition, Molecular Mechanisms, and Therapeutic Potential.Clinical Medicine Insights. Oncology · 2025Review
- The vaginal microbiome in HPV persistence and cervical cancer progression.Frontiers in cellular and infection microbiology · 2025Review
- Exploring Oral and Vaginal Probiotic Solutions for Women's Health from Puberty to Menopause: A Narrative Review.Microorganisms · 2024Review
- Oral and periodontal manifestation related during human papilloma virus infections: Update on early prognostic factors.Heliyon · 2024Review
- Display of porcine epidemic diarrhea virus spike protein B-cell linear epitope on Lactobacillus mucosae G01 S-layer surface induce a robust immunogenicity in mice.Microbial cell factories · 2024Article
- Evaluation of Immune Response to Mucosal Immunization with an Oral Probiotic-Based Vaccine in Mice: Potential for Prime-Boost Immunization against SARS-CoV-2.International journal of molecular sciences · 2023Article
- The potential use of bacteria and bacterial derivatives as drug delivery systems for viral infection.Virology journal · 2023Review
- Genetically predicted the causal relationship between gut microbiota and infertility: bidirectional Mendelian randomization analysis in the framework of predictive, preventive, and personalized medicine.The EPMA journal · 2023Article
- Human microbiomes in cancer development and therapy.MedComm · 2023Review
- Microbiota metabolites in the female reproductive system: Focused on the short-chain fatty acids.Heliyon · 2023Review
- Female reproductive tract-organ axes.Frontiers in immunology · 2023Review
- A replicative recombinant HPV16 E7 expression virus upregulates CD36 in C33A cells.Frontiers in microbiology · 2023Article
- Exploring the Molecular Pathogenesis, Pathogen Association, and Therapeutic Strategies against HPV Infection.Pathogens (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Most cervical cancer (CxCa) are related to persistent infection with high-risk human papillomavirus (HR-HPV) in the cervical mucosa, suggesting that an induction of mucosal cell-mediated immunity against HR-HPV oncoproteins can be a promising strategy to fight HPV-associated CxCa. From this perspective, many pre-clinical and clinical trials have proved the potential of lactic acid bacteria (LAB) genetically modified to deliver recombinant antigens to induce mucosal, humoral and cellular immunity in the host. Altogether, the outcomes of these studies suggest that there are several key factors to consider that may offer guidance on improvement protein yield and improving immune response. Overall, these findings showed that oral LAB-based mucosal HPV vaccines expressing inducible surface-anchored antigens display a higher potential to induce particularly specific systemic and mucosal cytotoxic cellular immune responses. In this review, we describe all LAB-based HPV vaccine investigations by reviewing databases from international studies between 2000 and 2020. Our aim is to promote the therapeutic HPV vaccines knowledge and to complete the gaps in this field to empower scientists worldwide to make proper decisions regarding the best strategies for the development of therapeutic HPV vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.